IONIS 2025 Q2
Earnings Overview & AI Insights

Earnings Performance

Summary of Financial Performance:

Ionis Pharmaceuticals delivered strong financial performance in Q2 2025, with revenue of $452 million, a twofold increase year-over-year. Non-GAAP net income reached $154 million, supported by robust revenue contributions from Trimgolta ($19 million in product sales, a threefold sequential increase), royalties from SPINRAZA and WAYLIVRA ($70 million), and a $280 million upfront payment from an R&D collaboration. Year-to-date revenue is up 70% to $584 million. FY2025 revenue guidance has been raised to $825-$850 million, with Trimgolta sales projected at $75-$80 million. Operating loss guidance has improved, now expected at $300-$325 million, while the year-end cash balance is projected to reach $2 billion.

Company Outlook & Strategy:

Ionis plans to launch multiple products targeting rare and prevalent diseases. Trimgolta’s early success has supported the upward revision of FY2025 guidance. Donidalorsen for hereditary angioedema (HAE) is on track for FDA approval by August 21, with modest revenue contributions expected this year. The pipeline remains strong, with upcoming launches including olezarsen for severe hypertriglyceridemia (SHTG) and zilgarnersen for Alexander disease. Management aims to sustain revenue growth and achieve positive cash flow in the coming years, supported by disciplined investments, strong commercial execution, and refinancing its 2026 convertible debt to preserve capital.

Key Industry Trends:

Ionis is focusing on addressing unmet medical needs in rare and severe conditions. The market for severe hypertriglyceridemia (SHTG) represents significant growth potential, with over 1 million patients in the U.S. experiencing high-risk triglyceride levels. Dissatisfaction among HAE patients with existing prophylactic treatments highlights demand for more effective solutions, creating opportunities for Donidalorsen. Increasing payer support and favorable reimbursement trends bolster commercial prospects for Ionis’s products.

Operational Highlights:

• Trimgolta Launch: Strong momentum with $19 million in Q2 sales, driven by effective patient identification, favorable reimbursement dynamics (90% of patients paying $0 out-of-pocket), and expanded prescriber base.
• Pipeline Progress: Phase 3 studies for olezarsen in SHTG (CORE and CORE-two) are the largest in this indication, enrolling ~1,100 participants. Top-line results are expected in September. Zilgarnersen for Alexander disease is progressing toward a pivotal readout later this year, representing its first clinical data in patients.
• Commercial Preparedness: The company is ready for the Donidalorsen U.S. launch, leveraging lessons from Trimgolta’s success.
• Innovation Day: Scheduled for October 7 to showcase pipeline advancements and discovery capabilities.

Challenges & Risks:

• Pipeline Uncertainty: The upcoming readout for zilgarnersen carries higher uncertainty due to the ultra-rare nature of Alexander disease and the lack of existing clinical data for this patient group.
• Costs: Non-GAAP operating expenses increased 8% year-over-year, including investments in Trimgolta and Donidalorsen launches.
• Regulatory Risks: Pending FDA approval for Donidalorsen and ongoing EU reviews may impact timelines for market entry.
• Competition: The company faces challenges in maintaining its first-mover advantage in competitive markets like HAE and SHTG.

Key Analyst Questions & Responses:

1. Q: What’s driving the revenue guidance increase?
   A: Management cited strong Trimgolta sales, a $280 million R&D payment, and improved pipeline outlook as key factors.

2. Q: How will Donidalorsen differentiate in the HAE market?
   A: Executives emphasized its efficacy, favorable safety profile, and patient-friendly auto-injector for monthly or bi-monthly administration.

3. Q: Any updates on pricing strategy for SHTG?
   A: Pricing decisions for olezarsen will follow upcoming study data and feedback from payers, with final pricing to be determined post-approval.

4. Q: Impact of upcoming CORE/CORE-two results?
   A: These studies could confirm olezarsen’s ability to address unmet needs in acute pancreatitis and severe triglyceride management, with top-line results expected in September.

5. Q: How does Trimgolta’s patient access program add value?
   A: Over 90% of patients paid $0 out-of-pocket, supported by the Ionis Pharmaceuticals Every Step Support Program, which facilitates insurance coordination and patient education.

Ionis Pharmaceuticals demonstrated strong commercial execution, pipeline progress, and financial discipline, positioning itself for sustained growth and transformative product launches.